These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1004 related articles for article (PubMed ID: 29912750)
21. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
22. Effect of peptide receptor radionuclide therapy (PRRT) with tandem isotopes - [90Y]Y/[177Lu]Lu-DOTATATE in patients with disseminated neuroendocrine tumours depending on [18F]FDG PET/CT qualification in Polish multicentre experience - do we need [18F]FDG PET/CT for qualification to PRRT? Zemczak A; Kołodziej M; Gut P; Królicki L; Kos-Kudła B; Kamiński G; Ruchała M; Pawlak D; Kunikowska J Endokrynol Pol; 2020; 71(3):240-248. PubMed ID: 32293704 [TBL] [Abstract][Full Text] [Related]
23. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of Adnan A; Basu S J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476 [TBL] [Abstract][Full Text] [Related]
24. The efficacy of Zhang J; Song Q; Cai L; Xie Y; Chen Y J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025 [TBL] [Abstract][Full Text] [Related]
25. Comparison of response evaluation in patients with gastroenteropancreatic and thoracic neuroendocrine tumors after treatment with [177Lu-DOTA0,Tyr3]octreotate. van Vliet EI; Krenning EP; Teunissen JJ; Bergsma H; Kam BL; Kwekkeboom DJ J Nucl Med; 2013 Oct; 54(10):1689-96. PubMed ID: 24084705 [TBL] [Abstract][Full Text] [Related]
26. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198 [TBL] [Abstract][Full Text] [Related]
27. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039 [TBL] [Abstract][Full Text] [Related]
28. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296 [TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of peptide receptor radionuclide therapy with Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603 [No Abstract] [Full Text] [Related]
32. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217 [TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with Sansovini M; Severi S; Ianniello A; Nicolini S; Fantini L; Mezzenga E; Ferroni F; Scarpi E; Monti M; Bongiovanni A; Cingarlini S; Grana CM; Bodei L; Paganelli G Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):490-499. PubMed ID: 27704193 [TBL] [Abstract][Full Text] [Related]
34. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630 [TBL] [Abstract][Full Text] [Related]
35. (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years' experience from a tertiary cancer care centre in India. Danthala M; Kallur KG; Prashant GR; Rajkumar K; Raghavendra Rao M Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1319-26. PubMed ID: 24570096 [TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]
37. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with Sampathirao N; Basu S J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019 [TBL] [Abstract][Full Text] [Related]
38. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427 [TBL] [Abstract][Full Text] [Related]